<DOC>
	<DOCNO>NCT01739894</DOCNO>
	<brief_summary>This single arm phase 2 trial evaluate efficacy tolerability intraperitoneal paclitaxel oxaliplatin capecitabine advance gastric cancer patient peritoneal metastasis and/or cancer cell peritoneal cytology . Twenty patient recruit study estimate period two year . Paclitaxel administer intraperitoneally 40mg/m2 Day 1 8 patient receive standard intravenous oxaliplatin 130mg/m2 Day 1 capecitabine 1000mg/m2 day 1-14 . The study hypothesize addition intraperitoneal paclitaxel chemotherapy improve treatment efficacy .</brief_summary>
	<brief_title>Feasibility Study Intraperitoneal Paclitaxel</brief_title>
	<detailed_description>The median survival patient unresectable gastric cancer treat systemic chemotherapy 12 month . In patient histologically proven unresectable recurrent gastric cancer limit peritoneum and/or cancer cell peritoneal cytology , combination i.p . paclitaxel systemic chemotherapy report median survival time 23.6 month . The peritoneal cytology turn negative 86 % patient . In updated report , gastrectomy perform 52 patient disappearance obvious shrinkage peritoneal metastasis . In cohort , median survival time ( MST ) 34.9 month . A phase III trial ( PHOENIX-GC trial ( Phase III study S-1 plus intravenous intraperitoneal paclitaxel versus S-1 plus cisplatin gastric cancer peritoneal metastasis ) ) compare intraperitoneal ( IP ) regimen systemic chemotherapy versus systemic therapy alone currently open recruitment Japan . The multidisciplinary treatment combine IP-containing chemotherapy surgery find safe effective gastric cancer patient peritoneal metastasis . A phase I study combine i.p . paclitaxel oxaliplatin S-1 , find dose limit toxicity dose level . Grade 3 neutropenia observe one patient recommend phase 2 dose ( RP2D ) i.p . paclitaxel 40 mg/m2 . In addition , grade 2 non-hematological toxicity observe anorexia ( n=6/12 ) , fatigue ( n=4/12 ) nausea ( n=2/12 ) . Both S-1 capecitabine orally available fluoropyrimidine . When combined oxaliplatin , S-1 capecitabine find equally active well tolerate advanced gastric cancer patient . As S-1 yet widely available worldwide , combination capecitabine platinum chemotherapy still one commonly adopt chemotherapy regimen patient advance gastric cancer . In study , intend assess efficacy feasibility combine weekly i.p . paclitaxel oxaliplatin capecitabine .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically proven unresectable recurrent adenocarcinoma stomach gastroesophageal junction Patients without prior systemic treatment . Patients complete postoperative adjuvant chemotherapy ( radiotherapy ) 180 day may enrol Peritoneal metastasis and/or cancer cell peritoneal cytology Age &gt; 21 year Eastern Cooperative Oncology Group performance status 02 Adequate bone marrow function ( neutrophil count &gt; 1500/mm3 , hemoglobin &gt; 8.0 g/dl platelet count &gt; 100 000/mm3 ) Adequate liver function ( bilirubin , AST ( aspartate aminotransferase ) /ALT ( alanine aminotransferase ) within upper limit normal ) Adequate renal function ( serum creatinine within upper limit normal ) Expected survival &gt; 3 month Able take orally Able understand willingness sign write informed consent document The effect propose regimen develop human fetus recommend therapeutic dose unknown . For reason antitumor agent well therapeutic agent use trial know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Metastasis distant organ site ( liver , lungs bone ) When trastuzumab consider palliative chemotherapy Known allergy taxane , fluoropyrimidine oxaliplatin Previous malignancy gastric cancer diagnose last 5 year except basal cell carcinoma skin preinvasive cancer cervix Patients reproductive potential refuse use adequate mean contraception ( include male patient ) Significant disease condition , investigator 's opinion , would exclude patient study Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Advanced gastric cancer</keyword>
	<keyword>unresectable gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>peritoneal metastasis</keyword>
	<keyword>cancer cell peritoneal cytology</keyword>
</DOC>